Assessments of ADAS-Cog administration quality are comparable across expert and non-expert reviewers
This poster was presented at the ISCTM Annual Scientific Meeting in February 2023.
New Commercial Partnership and Further Scientific Validation for NeuroVocalix
Cambridge Cognition is pleased to announce the second commercial partnership with a leading pharmaceutical company, for its NeuroVocalixTM platform. NeuroVocalixTM is a unique voice biomarker technology and the product was launched last year and recently presented ground-breaking demonstrable evidence of the potential at a major global Alzheimer’s conference.
NeuroVocalix platform ready for clinical trials
NeuroVocalix enables novel voice-based cognitive assessments to be delivered directly to patients through mobile and tele-health platforms, helping to improve outcomes in clinical trials, aid clinical decision-making and play an important role in the management of long-term conditions such as chronic pain.